Cloned Livestock Poised To Receive FDA Clearance
By Jane Zhang, John Miller, and Lauren Etter,
Wall Street Journal
| 01. 04. 2008
Get ready for a food fight over milk and meat from cloned animals and their offspring.
After more than six years of wrestling with the question of whether meat and milk from them are safe to eat, the Food and Drug Administration is expected to declare as early as next week that they are.
The FDA had asked producers of cloned livestock not to sell food products from such animals pending its ruling on their safety. It isn't clear whether the FDA will lift this voluntary hold.
While many consumer groups still oppose it, the FDA declaration that cloned animal products are safe would be a milestone for a small cadre of biotech companies that want to make a business out of producing copies of prize dairy cows and other farm animals -- effectively taking the selective breeding practiced on farms for centuries to the cutting edge.
Because of the price tag -- cloned cattle cost $15,000 to $20,000 per copy -- most of the cloned animals will be used for breeding, and it will be three to five years...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...